Phase I, first in human study of SI-101 in patients with relapsed/refractory non-Hodgkin lymphoma

Status: Planning

Phase of Trial: Phase I/II

Latest Information Update: 15 Jul 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs SI 101 (Primary)
Indications Carcinoma; Cutaneous T-cell lymphoma; Head and neck cancer; Non-Hodgkin's lymphoma; Solid tumours
Focus Adverse reactions; First in man; Therapeutic Use

11 Jul 2023 According to Incyte media release, today announced appointment of Jelle Kijlstra, MD, MBA as its new Chief Medical Officer. Dr. Kijlstra and he will responsible for advancing development of SIRPant-M (SI-101) and ongoing Phase 1 clinical study of SI-101 in relapsed/refractory Non-Hodgkins Lymphomas and the filing of a solid tumor-focused IND later this year.
03 May 2023 New trial record
01 May 2023 According to Incyte media release, company intends to initiate this study in patients with relapsed refractory non-Hodgkin lymphoma in Q3 of 2023.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com